InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Explore the full record of transactions filed by Eisner Mark, VP Exécutif. Director active across 2 companies, notably Vir Biotechnology, Inc.. In total, 12 reports have been recorded. Total volume traded: €26k. The latest transaction was disclosed on 24 February 2026 — Cession. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
US$13,0621,616 shares@ US$8.08270.0016% mcap100.0% of flow
Common Stock
SEC:0001628280-26-012394·
€13,0621,616 shares@ €8.08270.0016% mcap50.0% of flow
Common Stock
SEC:0001628280-26-012394:0·
€10,2921,141 shares@ €9.01992.8% of flow
Common Stock
SEC:0001209191-22-034041:0·
€69,9336,442 shares@ €10.855918.9% of flow
Common Stock
SEC:0001209191-22-022095:0·
€9,180756 shares@ €12.14352.5% of flow
Common Stock
SEC:0001209191-22-015366:0·
060,000 shares0
Common Stock
SEC:0001209191-22-010452:0·
€91,7737,043 shares@ €13.030365.5% of flow
Common Stock
SEC:0001209191-22-001743·
€91,7737,043 shares@ €13.030324.8% of flow
Common Stock
SEC:0001209191-22-001743:0·
€48,4334,338 shares@ €11.164834.5% of flow
Common Stock
SEC:0001209191-21-067780·
€48,4334,338 shares@ €11.164813.1% of flow
Common Stock
SEC:0001209191-21-067780:0·
074,520 shares0
Common Stock
SEC:0001209191-21-059869·
074,520 shares0
Common Stock
SEC:0001209191-21-059869:0·
12 of 12 declarations
About Eisner Mark
Mark Eisner is the Executive Vice President and Chief Medical Officer at Vir Biotechnology, Inc. and FibroGen Inc. He oversees the medical and research operations of the companies, ensuring innovation and compliance. Eisner plays a key role in developing medical treatments and improving patient outcomes.
